Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ...
Pharmabiz22h
Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment
Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment: Geneva Tuesday, October 22, 2024, 13:00 Hrs [IST] Relief Therapeutics ...
Seeking Alpha5d
RLFTY Relief Therapeutics Holding SA
In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution ...
Yahoo Finance4d
Relief Therapeutics Holding SA (RLF.SW)
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined ...